3 Reasons Why Growth Investors Shouldn't Overlook Regeneron (REGN)Zacks Investment Research • 10/08/21
Regeneron (REGN) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research • 10/06/21
Here's Why Regeneron (REGN) is Poised for a Turnaround After Losing 16% in 4 WeeksZacks Investment Research • 10/04/21
New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19PRNewsWire • 09/30/21
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19PRNewsWire • 09/29/21
FDA Accepts Libtayo® (cemiplimab-rwlc) for Priority Review for Advanced Cervical CancerPRNewsWire • 09/28/21
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Cantor Fitzgerald Virtual Global Healthcare 2021 Conference (Transcript)Seeking Alpha • 09/27/21
Regeneron (REGN) Antibody Cocktail REGEN-COV Gets WHO RecommendationZacks Investment Research • 09/27/21